TARGETED PORTFOLIO

A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products. The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. We offer high quality, affordable generic medications that help reduce healthcare costs around the world. 

Alvogen also sells and markets a growing portfolio of OTC (over-the-counter) medicines and medical devices. In November 2013, the company announced that it would invest over $500 million in the development of biopharmaceuticals through its sister company, Alvotech. 

Marketed products
350
Generic projects in pipeline
200

  

PATIENTS SAFETY

Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information over the lifecycle of each product.

Pharmacovigilance

LOCAL TEAMS

Alvogen has commercial operations in more than 30 countries around the world, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania. Connect directly with our local temas for more information on products, business opportunities and more.

Offices overview

Lines of business

Our lines of business include: development, contract manufacturing and research (CMO), sales of generic and brand medicines, biosimilars and OTC’s. Our portfolio includes molecules for conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology.

Read more